Agios Pharmaceuticals — Third Quarter 2026 Earnings Summary

Agios Pharmaceuticals reported third-quarter 2026 net product revenues of $55.4 million for mitapivat, driven by the U.S. commercial launch of AQVESME for thalassemia and early access programs in Europe. The company achieved a net loss of $65.0 million for the quarter, a significant improvement from the $103.4 million loss in the same period of 2025, while maintaining $907.0 million in cash and marketable securities. Regulatory updates include a new PDUFA goal date of February 1, 2027, for the supplemental New Drug Application of mitapivat for sickle cell disease. Additionally, Agios plans to reduce its research and development headcount by over 100 roles by the end of 2026 to support its path toward non-GAAP profitability in 2028.